Former pharma executive Alex Azar has a new title: secretary of Health and Human Services.
The Senate voted 55-43 to confirm the nomination of Azar, the former head of pharmaceutical giant Eli Lilly’s U.S. operations, to serve in the role vacated by Tom Price, M.D.
Price, a former congressman, resigned in September after eight months on the job due to controversy over use of private planes for government travel using taxpayer money. President Donald Trump soon tapped Azar to fill the role, saying he would be “a star for better healthcare and lower drug prices!”
Azar has unique qualifications because he has already worked at HHS. He served as general counsel for the department from 2001 to 2005 and then became the deputy secretary under then-HHS Secretary Mike Leavitt, a position he held for two years.
But not everyone was convinced. Many Democrats opposed his nomination from the beginning, noting his ties to the pharmaceutical industry and questioning whether he would be committed to lowering drug prices. The skyrocketing cost of prescription drugs came up frequently during the course of his confirmation hearings during the Senate vote on Tuesday to advance his nomination.
On the Senate floor today, several Democrats, including Ron Wyden, D-Ore., ranking member of the Senate Finance Committee, Patty Murray, D-Wash., and Chris Murphy, D-Conn., said they would vote against his nomination. In addition to their concerns that drug prices rose under Azar’s watch while he was at Eli Lilly, they also fear he will work with the Trump administration to sabotage the Affordable Care Act.
But Senate Majority Leader Mitch McConnell, R-Ky., praised Azar, whom he called the “right man for the job.”
“In his impressive testimony before the Finance Committee, Mr. Azar discussed his intention to confront head-on the opioid crisis that is hurting so many families across the country, including in my home state of Kentucky. He made clear that he will place an important priority on prevention, education and enforcement to halt the advance of this scourge,” McConnell said.
As the head of HHS, Azar will be responsible for overseeing $1.13 trillion in department spending and supervising research and administering health programs, including Medicare and Medicaid.
By Ilene MacDonald
Source: Fierce Healthcare
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
